659 related articles for article (PubMed ID: 26718488)
1. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
2. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Xue M; Amin M; Shahtahmassebi N; Malaekeh-Nikouei B
Eur J Pharm Biopharm; 2015 Jan; 89():248-58. PubMed ID: 25511563
[TBL] [Abstract][Full Text] [Related]
3. Amphiphilic hyperbranched polyester coated rod mesoporous silica nanoparticles for pH-responsive doxorubicin delivery.
Bafkary R; Ahmadi S; Fayazi F; Karimi M; Fatahi Y; Ebrahimi SM; Atyabi F; Dinarvand R
Daru; 2020 Jun; 28(1):171-180. PubMed ID: 32006342
[TBL] [Abstract][Full Text] [Related]
4. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance.
Yu M; Han S; Kou Z; Dai J; Liu J; Wei C; Li Y; Jiang L; Sun Y
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):323-332. PubMed ID: 28393563
[TBL] [Abstract][Full Text] [Related]
6. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
[TBL] [Abstract][Full Text] [Related]
7. Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies.
Ansari L; Jaafari MR; Bastami TR; Malaekeh-Nikouei B
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):594-606. PubMed ID: 29688064
[TBL] [Abstract][Full Text] [Related]
8. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
9. The properties of mesoporous silica nanoparticles functionalized with different PEG-chain length via the disulfide bond linker and drug release in glutathione medium.
Xie Z; Gong H; Liu M; Zhu H; Sun H
J Biomater Sci Polym Ed; 2016; 27(1):55-68. PubMed ID: 26540096
[TBL] [Abstract][Full Text] [Related]
10. Surface decorated nanoparticles as surrogate carriers for improved transport and absorption of epirubicin across the gastrointestinal tract: Pharmacokinetic and pharmacodynamic investigations.
Tariq M; Alam MA; Singh AT; Panda AK; Talegaonkar S
Int J Pharm; 2016 Mar; 501(1-2):18-31. PubMed ID: 26812610
[TBL] [Abstract][Full Text] [Related]
11. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo.
Lin D; Cheng Q; Jiang Q; Huang Y; Yang Z; Han S; Zhao Y; Guo S; Liang Z; Dong A
Nanoscale; 2013 May; 5(10):4291-301. PubMed ID: 23552843
[TBL] [Abstract][Full Text] [Related]
12. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
13. The packaging of siRNA within the mesoporous structure of silica nanoparticles.
Li X; Xie QR; Zhang J; Xia W; Gu H
Biomaterials; 2011 Dec; 32(35):9546-56. PubMed ID: 21906804
[TBL] [Abstract][Full Text] [Related]
14. Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs.
Jia L; Shen J; Li Z; Zhang D; Zhang Q; Duan C; Liu G; Zheng D; Liu Y; Tian X
Int J Pharm; 2012 Dec; 439(1-2):81-91. PubMed ID: 23078857
[TBL] [Abstract][Full Text] [Related]
15. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.
Li X; Chen Y; Wang M; Ma Y; Xia W; Gu H
Biomaterials; 2013 Jan; 34(4):1391-401. PubMed ID: 23164421
[TBL] [Abstract][Full Text] [Related]
16. Differential Effects of Polymer-Surface Decoration on Drug Delivery, Cellular Retention, and Action Mechanisms of Functionalized Mesoporous Silica Nanoparticles.
You Y; Hu H; He L; Chen T
Chem Asian J; 2015 Dec; 10(12):2744-54. PubMed ID: 26248202
[TBL] [Abstract][Full Text] [Related]
17. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
[TBL] [Abstract][Full Text] [Related]
18. Polydopamine coated hollow mesoporous silica nanoparticles as pH-sensitive nanocarriers for overcoming multidrug resistance.
Shao M; Chang C; Liu Z; Chen K; Zhou Y; Zheng G; Huang Z; Xu H; Xu P; Lu B
Colloids Surf B Biointerfaces; 2019 Nov; 183():110427. PubMed ID: 31408782
[TBL] [Abstract][Full Text] [Related]
19. Unsaturated nitrogen-rich polymer poly(l-histidine) gated reversibly switchable mesoporous silica nanoparticles using "graft to" strategy for drug controlled release.
Mu S; Liu Y; Wang T; Zhang J; Jiang D; Yu X; Zhang N
Acta Biomater; 2017 Nov; 63():150-162. PubMed ID: 28873341
[TBL] [Abstract][Full Text] [Related]
20. Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells.
Xu W; Ge P; Niu B; Zhang X; Liu J; Xie J
J Colloid Interface Sci; 2018 Oct; 527():141-150. PubMed ID: 29787950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]